Listen to an interview with lead author of NYFD cancer study
11 Sep 2011 by Wendi Lewis under News, Research/Treatment
Earlier this month, in anticipation of the 10th anniversary of 9/11, The Lancet published a study of cancer risk in New York City firefighters who were first responders to Ground Zero at the World Trade Center (WTC). The study, conducted seven years after the attacks, was both the “first firefighter study on the effects of 9/11 and cancer, but it is also the largest firefighter cancer study ever done,” according to Dr. David J. Prezant, Chief Medical Officer at the NYFD and the lead author of the study. (more…)
View Comments to “Listen to an interview with lead author of NYFD cancer study”
What Is Malignant Mesothelioma?………..
http://www.infomesotheliomas.blogspot.com
One thing that was upsetting about this story was how the first responders were lied to about asbestos, more information shortly at http://www.asbestosremovalsperth.net.au
I don’t think they were lied to. Asbestos was known to be present in the world trade center there was no conspiracy or cover up on this issue. However the heroes of 911 knew the dangers and responded anyway. Close family members of mine have died from asbestos exposure and i have started a site http://www.safeasbestosremoval.com.au. I am to provide all the information you need to safely remove asbestos yourself, because the next wave of asbestos victims is going to be DIY home renovators.
A new study of the population of Perth Western Australia is showing an increase in asbestos diseases, this is due to DIY renovators, this study shows that even a one time exposure to asbestos is enough to cause major problems. To all DIY asbestos removalists be carefull when removing asbestos
Asbestos has been widely used in many building products because of its tensile strength and chemical and thermal resistance.
Research led by investigators at Memorial Sloan-Kettering Cancer Center has identified a previously unknown mechanism of resistance to the newly approved melanoma drug, vemurafenib, an oral targeted therapy used to treat advanced melanoma whose tumors contain a mutation in a gene called BRAF. The results of the study are published in the November 23rd advanced online edition of the journal Nature.
Leave a Reply